Ovid Looks To Epilepsy – And Beyond – For Candidate OV350

Ovid anticipates its deal to sell part of its interest in soticlestat milestones and royalties to Ligand will take it through 2026, while it looks to develop its KCC2-targeting OV350 for psychiatric disorders.

Ovid announced its third quarter 2023 earnings • Source: Shutterstock

Ovid Therapeutics, Inc. is expanding its research and development efforts beyond its historical focus on seizure disorders and into areas such as psychiatric disorders and pain, the company highlighted during its third quarter sales and earnings call, building from the library of KCC2-targeting drugs that it acquired from AstraZeneca PLC after selling its interest in soticlestat back to Takeda Pharmaceutical Co. Ltd.

New York-based Ovid announced its Q3 financials on 3 November, reporting $109,000 in revenue and cash, cash equivalents and marketable...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.